Leadership & Pay ·
Whitehawk Therapeutics, Inc. increased its authorized board size from nine to ten directors and appointed Vijay…
WHWKWhitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc. increased its authorized board size from nine to ten directors and appointed Vijay Iyengar, M.D., as a Class III director effective September 9, 2026. Dr. Iyengar brings extensive oncology leadership experience from previous roles at Incyte Corporation and Novartis. As part of his appointment, he received an initial stock option award to purchase 76,080 shares, vesting monthly over three years, along with a $40,000 annual base retainer and standard indemnification. Whitehawk Therapeutics is a clinical-stage oncology company developing antibody-drug conjugate (ADC) cancer treatments.